Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials
Open Access
- 2 September 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (46) , 4902-4916
Abstract
The optimal antithrombotic therapy in patients with device-detected atrial fibrillation (DDAF) is unknown. Concomitant vascular disease can modify the benefits and risks of anticoagulation. These pre-specified analyses of the NOAH-AFNET 6 (n=2534 patients) and ARTESiA (n=4012 patients) trials compared anticoagulation to no anticoagulation in patients with DDAF with or without vascular disease, defined as prior stroke/transient ischemic attack, coronary or peripheral artery disease. Efficacy outcomes were the primary outcomes of both trials, a composite of stroke, systemic arterial embolism (SE), myocardial infarction, pulmonary embolism or cardiovascular death, and stroke or SE. Safety outcomes were major bleeding or major bleeding and death. In patients with vascular disease (NOAH-AFNET 6 56%, ARTESiA 46.0%), stroke, myocardial infarction, systemic or pulmonary embolism, or cardiovascular death occurred at 3.9%/patient-year with and 5.0%/patient-year without anticoagulation (NOAH-AFNET 6), and 3.2%/patient-year with and 4.4%/patient-year without anticoagulation (ARTESiA). Without vascular disease, outcomes were equal with and without anticoagulation (NOAH-AFNET 6 2.7%/patient-year, ARTESiA 2.3%/patient-year in both randomised groups). Meta-analysis found consistent results across both trials (I2heterogeneity=6%) with a trend for interaction with randomised therapy (pinteraction=0.08). Stroke/SE behaved similarly. Anticoagulation increased major bleeding in vascular disease patients (edoxaban 2.1%/patient-year, no anticoagulation 1.3%/patient-year; apixaban 1.7%/patient-year; no anticoagulation 1.1%/patient-year; incidence rate ratio 1.55 [1.10-2.20]) and without vascular disease (edoxaban 2.2%/patient-year; no anticoagulation 0.6%/patient-year; apixaban 1.4%/patient-year; no anticoagulation 1.1%/patient-year, incidence rate ratio 1.93 [0.72-5.20]). Patients with DDAF and vascular disease are at higher risk of stroke and cardiovascular events and may derive a greater benefit from anticoagulation than patients with DDAF without vascular disease.Keywords
This publication has 26 references indexed in Scilit:
- Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial FibrillationJACC, 2024
- Anticoagulation with Edoxaban in Patients with Atrial High-Rate EpisodesNew England Journal of Medicine, 2023
- Effects of Aspirin for Primary Prevention in Persons with Diabetes MellitusNew England Journal of Medicine, 2018
- Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined SourceNew England Journal of Medicine, 2018
- Rivaroxaban with or without Aspirin in Stable Cardiovascular DiseaseNew England Journal of Medicine, 2017
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsThe Lancet, 2014
- Subclinical Atrial Fibrillation and the Risk of StrokeNew England Journal of Medicine, 2012
- Apixaban in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Effect of Clopidogrel Added to Aspirin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009